The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 16, 2012
Filed:
Jan. 04, 2005
Michael L. Edwards, Morristown, NJ (US);
Paul J. Cox, Millington, NJ (US);
Shelley Amendola, Bedminster, NJ (US);
Stephanie D. Deprets, Paris, FR;
Timothy A. Gillespy, Hillsboro, NJ (US);
Christopher D. Edlin, Newark, GB;
Andrew D. Morley, Macclesfield, GB;
Charles J. Gardner, Royersford, NJ (US);
Brian Pedgrift, Flemington, NJ (US);
Herve Bouchard, Thiais, FR;
Didier Babin, Montigny, FR;
Laurence Gauzy, Paris, FR;
Alain Le-brun, Vigneux, FR;
Tahir N. Majid, Hoboken, NJ (US);
John C. Reader, Cambridge, GB;
Lloyd J. Payne, Cambridgeshire, GB;
Nawaz M. Khan, Cambridge, GB;
Michael Cherry, Stuffolk, GB;
Michael L. Edwards, Morristown, NJ (US);
Paul J. Cox, Millington, NJ (US);
Shelley Amendola, Bedminster, NJ (US);
Stephanie D. Deprets, Paris, FR;
Timothy A. Gillespy, Hillsboro, NJ (US);
Christopher D. Edlin, Newark, GB;
Andrew D. Morley, Macclesfield, GB;
Charles J. Gardner, Royersford, NJ (US);
Brian Pedgrift, Flemington, NJ (US);
Herve Bouchard, Thiais, FR;
Didier Babin, Montigny, FR;
Laurence Gauzy, Paris, FR;
Alain Le-Brun, Vigneux, FR;
Tahir N. Majid, Hoboken, NJ (US);
John C. Reader, Cambridge, GB;
Lloyd J. Payne, Cambridgeshire, GB;
Nawaz M. Khan, Cambridge, GB;
Michael Cherry, Stuffolk, GB;
Aventis Pharmaceuticals Inc., Bridgewater, NJ (US);
Abstract
The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.